Abstrakt

Low-dose computed tomography (LDCT) is the diagnostic core of lung cancer screening programmes and enables detection of early-stage disease, leading to a significant reduction in lung cancer mortality. Advances in hardware, dose optimisation, software-assisted reading and standardized systems such as Lung-RADS improve sensitivity, reproducibility and quality assurance. LDCT additionally provides information on cardiovascular and pulmonary comorbidities. However, limitations include false-positive and false-negative findings, cumulative radiation exposure, resource demands and ethical as well as methodological challenges. Structured quality management, collaboration with specialised centres and continuous evaluation – including innovative biomarkers and radiomics – are essential for sustainable programme success.

Autoreninformation

Autoren

• T. Elgeti
• G. Böning
• J. Vogel-Claussen

Abteilungen

• Klinik für Radiologie, Charité – Universitätsmedizin Berlin, Berlin

Adresse

Prof. Dr. med. Thomas Elgeti
Klinik für Radiologie
Charité – Universitätsmedizin Berlin
Hindenburgdamm 30
12203 Berlin
Email: [email protected]

Citation